Metabolism of steroidal anti-inflammatory antedrugs in vitro: Methyl 3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene-16α- carboxylate; Its 9α-fluorinated, and their 21-O-acyl derivatives

Steroids

Volumn 68, Issue 4, 2003, Pages 315-319

  Park, Kwan Kyun ^a   Ko, Dong Hoon ^a   You, Zhengqing ^a   Lee, Henry Joung ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Antedrugs; Anti inflammatory agents; Drug design; Hydrolysis; Metabolism; Steroids

Indexed keywords

21 ACETYLMETHYL 3,20 DIOXO 11BETA,17ALPHA,21 TRIHYDROXY 1,4 PREGNADIENE 16 ALPHA CARBOXYLATE; 21 ACETYLMETHYL 3,20 DIOXO 9 ALPHA FLUORO 11BETA,17 ALPHA,21 TRIHYDROXY 1,4 PREGNADIENE 16 ALPHA CARBOXYLATE; 21 PIVALYLMETHYL 3,20 DIOXO 9 ALPHA FLUORO 11BETA,17ALPHA,21 TRIHYDROXY 1,4 PREGNADIENE 16 ALPHA CARBOXYLATE; 21 PROPIONYLMETHYL 3,20 DIOXO 9 ALPHA FLUORO 11BETA,17ALPHA,21 TRIHYDROXY 1,4 PREGNADIENE 16 ALPHA CARBOXYLATE; 21 VALERYLMETHYL 3,20 DIOXO 9 ALPHA FLUORO 11BETA,17ALPHA,21 TRIHYDROXY 1,4 PREGNADIENE 16 ALPHA CARBOXYLATE; ANTIINFLAMMATORY AGENT; CARBOXYLIC ACID DERIVATIVE; METHYL 3,20 DIOXO 11BETA,17ALPHA,21 TRIHYDROXY 1,4 PREGNADIENE 16 ALPHA CARBOXYLATE; METHYL 3,20 DIOXO 9 ALPHA FLUORO 11BETA,17ALPHA,21 TRIHYDROXY 1,4 PREGNADIENE 16 ALPHA CARBOXYLATE; STEROID; STEROID 16 CARBOXYLATE; UNCLASSIFIED DRUG;

ACIDITY; ANALYTIC METHOD; ARTICLE; DRUG ACTIVITY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SYNTHESIS; IN VITRO STUDY; MALE; METABOLITE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PLASMA; RAT; SYSTEMIC CIRCULATION;

EID: 0038441574     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(03)00039-4     Document Type: Article

References (24)

1. Hench P.S., Kendall E.C., Stocumb C.H., Pilley H.F. Effect of hormone of adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis; preliminary report. Proc. Staff. Meet Mayo Clin. 24:1949;181-197.
2. Laan R.F., Jansen T.L., van Riel P.L. Glucocorticoids in the management of rheumatoid arthritis. Rheumatology. 38:1999;6-12.
3. Weisman M.H. Corticosteroids in the treatment of rheumatologic diseases. Curr. Opinion Rheumatol. 8:1996;188-194.
4. Jacobsen S. Use of glucocorticoids in rheumatoid arthritis. Ugeskrift for Laeger. 162:2000;770-772.
5. Scadding G.K. Corticosteroids in the treatment of pediatric allergic rhinitis. J. Allergy Clin. Immunol. 108:2001;S59-S64.
6. Abdusametov R.Kh., Abdusametova Sh.R. Treatment of certain dermatoses with corticosteroid preparations. Vestnik Dermatologii I Venerologii. 44:1970;23-27.
7. Masi A.T., Chrousos G.P. Hypothalamic-pituitary adrenal glucocorticoid axis function in rheumatoid arthritis. J. Rheumatol. 23:1996;577-581.
8. Nishimura J., Ikuyama S. Glucocorticoid-induced osteoporosis: pathogenesis and management. J. Bone Miner. Metab. 18:2000;3350-3352.
9. Sambrook P., Raj A., Hunter D., Naganathan V., Mason R., Robinson B. Osteoporosis with low dose corticosteroids: contribution of underlying disease effects and discriminatory ability of ultrasound versus bone densitometry. J. Rheumatol. 28:2001;1063-1067.
10. Alekseev E.I., Sshakhbazian I.E., Ulybina O.V., Khudoleeva E.I. Effectiveness and side-effects of long-term treatment with glucocorticoids in patients with juvenile rheumatoid arthritis. Kimicheskala Meditsina. 79:2001;33-38.
11. Lee H.J., Cooperwood J.S., You Z., Ko D.-H. Prodrug and antedrug: two diametrical approaches in designing safer drugs. Arch. Pharm. Res. 25:2002;111-136.
12. Lee H.J., Soliman M.R.I. Anti-inflammatory steroids without pituitary adrenal suppression. Science. 215:1982;989-991.
13. Kimura T. Antedrugs and pro-antedrugs of corticosteroids. Jpn. J. Clinic. Med. 52:1994;691-697.
14. Procopiou P.A., Biggadike K., English A.F., Farrell R.M., Hagger O.N., Hancock A.P.et al. Novel glucocorticoid antedrugs possessing a 17β-(γ-lactone) ring. J. Med. Chem. 44:2001;602-612.
15. Little U., Bodor N., Loftsson T. Soft drugs based on hydrocortisone: the inactive metabolite approach and its application to steroidal anti-inflammatory agents. Pharm. Res. 16:1999;961-967.
16. Sawa M., Tsukamoto T., Kiyoi T., Kurogawa K., Nakajima F., Nakada Y.et al. New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs. J. Med. Chem. 45:2002;930-936.
17. You Z., Heiman A.S., Hudson C.E., Lee H.J. Effect of chirality at C-20 of methyl 11β,17α,20-trihydroxyl-3-oxo-1,4-pregnadien-21-oate derivatives on anti-inflammatory activity. Steroids. 67:2002;353-359.
18. Heiman A.S., Hickman F., Ko D.-H., Lee H.J. New steroidal anti-inflammatory antedrugs bind to macrophage glucocorticoid receptor and inhibit nitric oxide generation. Steroids. 63:1998;644-649.
19. Ko D.-H., Heiman A.S., Hudson C.E., Lee H.J. New steroidal anti-inflammatory antedrugs: methyl 3,20-dioxo-9α-fluoro-11β,17α,21-trihydroxy-1,4- pregnadiene-16α-carboxylate and its 21-O-acyl derivatives. Steroids. 67:2002;211-219.
20. Ueno H., Maruyama A., Miyake M., Nakao E., Nakao K., Umezu K.et al. Synthesis and evaluation of anti-inflammatory activities of a series of corticosteroid 17α-esters containing a functional group. J. Med. Chem. 34:1991;2468-2473.
21. Suzuki T., Sato E., Tada H., Tojima Y. Examination of local anti-inflammatory activities of new steroids, hemisuccinyl methyl glycolates. Biol. Pharm. Bull. 22:1999;816-821.
22. Jensen E., Bundgaard H. N-substituted (aminoethyl)benzoate 21-esters of corticosteroids as water-soluble, solution-stable and biolabile prodrugs. Acta Pharmaceutica Nordica. 4:1992;3542.
23. Hochhaus G., Chen L.S., Ratka A., Druzgala P., Howes J., Bodor N.et al. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J. Pharm. Sci. 81:1992;1210-1215.
24. Bomscheuer U.T. Microbial carboxyl esterases: classification, properties and application in biocatalysis. FEMS Microbiol. Rev. 733:2002;1-9.